drugset / Trial / NCT03934099
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Timeline
- Start
- 2019-12-02
- Primary completion
- 2021-05-03
- Completion
- 2021-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tigulixostat | Small molecule | 50 mg | — |
| Subject | Tigulixostat | Small molecule | 100 mg | — |
| Subject | Tigulixostat | Small molecule | 200 mg | — |